BioAge Labs (NASDAQ:BIOA) Price Target Raised to $52.00

BioAge Labs (NASDAQ:BIOA) had its price target hoisted by Citigroup from $15.00 to $52.00 in a report released on Tuesday,Benzinga reports. The brokerage currently has a buy rating on the stock.

Other research analysts have also issued reports about the stock. Piper Sandler assumed coverage on shares of BioAge Labs in a research note on Tuesday, January 27th. They set an “overweight” rating on the stock. Wall Street Zen raised BioAge Labs from a “sell” rating to a “hold” rating in a research report on Tuesday, February 3rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioAge Labs in a research report on Tuesday, January 27th. Morgan Stanley set a $23.00 target price on BioAge Labs in a research note on Wednesday, February 4th. Finally, Oppenheimer assumed coverage on BioAge Labs in a research note on Wednesday, February 25th. They issued an “outperform” rating and a $60.00 price target on the stock. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, BioAge Labs currently has a consensus rating of “Moderate Buy” and an average target price of $45.00.

BioAge Labs Trading Down 0.9%

Shares of BIOA opened at $19.89 on Tuesday. The company’s fifty day simple moving average is $19.53 and its 200 day simple moving average is $11.91. BioAge Labs has a 1-year low of $2.88 and a 1-year high of $24.00. The company has a market cap of $713.06 million, a price-to-earnings ratio of -13.09 and a beta of 1.22.

Insider Buying and Selling

In related news, CEO Kristen Fortney sold 233,107 shares of BioAge Labs stock in a transaction that occurred on Tuesday, January 13th. The shares were sold at an average price of $18.12, for a total transaction of $4,223,898.84. Following the sale, the chief executive officer directly owned 976,949 shares of the company’s stock, valued at approximately $17,702,315.88. The trade was a 19.26% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Dov A. Md Goldstein sold 27,000 shares of the company’s stock in a transaction dated Tuesday, January 13th. The stock was sold at an average price of $19.70, for a total value of $531,900.00. Following the completion of the transaction, the chief financial officer directly owned 22,408 shares of the company’s stock, valued at approximately $441,437.60. The trade was a 54.65% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 267,540 shares of company stock worth $4,895,168. Company insiders own 20.82% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in BIOA. CWM LLC boosted its position in BioAge Labs by 39.9% during the fourth quarter. CWM LLC now owns 3,693 shares of the company’s stock valued at $49,000 after acquiring an additional 1,053 shares during the last quarter. Russell Investments Group Ltd. bought a new position in BioAge Labs during the third quarter worth $27,000. China Universal Asset Management Co. Ltd. bought a new stake in BioAge Labs in the fourth quarter valued at $77,000. Police & Firemen s Retirement System of New Jersey acquired a new position in shares of BioAge Labs during the second quarter valued at about $27,000. Finally, Nisa Investment Advisors LLC raised its holdings in shares of BioAge Labs by 4,219.4% during the fourth quarter. Nisa Investment Advisors LLC now owns 10,237 shares of the company’s stock valued at $135,000 after purchasing an additional 10,000 shares during the period.

BioAge Labs Company Profile

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.